Justin Kisner

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

Cooley advised AIRO Group Holdings, a company specializing in advanced aerospace and defense technologies, on its $69 million initial public offering (IPO).

Cooley advised Heliogen, a provider of on-demand clean energy technology solutions, on its definitive agreement with Zeo Energy, a Florida-based provider of residential solar and energy efficiency solutions, representing the culmination of Heliogen’s review of strategic alternatives and pursuant to which Zeo will acquire all of Heliogen’s outstanding equity securities in an all-stock transaction.

Cooley previously advised Impact Analytics, a leader in artificial intelligence (AI)-native innovation and the only provider of an end-to-end platform for pricing, merchandising and supply chain on the close of its Series D funding round led by Blue Cloud Ventures.

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.